VYNDAMAX
Drug
Pfizer Inc.
Total Payments
$486,617
Transactions
6,339
Doctors
4,345
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $356,030 | 3,160 | 2,275 |
| 2023 | $91,006 | 2,300 | 1,845 |
| 2022 | $38,992 | 805 | 643 |
| 2021 | $575.95 | 72 | 49 |
| 2020 | $6.10 | 1 | 1 |
| 2019 | $6.10 | 1 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $170,947 | 46 | 35.1% |
| Food and Beverage | $129,376 | 5,724 | 26.6% |
| Consulting Fee | $107,394 | 27 | 22.1% |
| Travel and Lodging | $39,689 | 76 | 8.2% |
| Unspecified | $27,080 | 13 | 5.6% |
| Space rental or facility fees (teaching hospital only) | $9,200 | 4 | 1.9% |
| Education | $2,930 | 449 | 0.6% |
Payments by Type
General
$459,537
6,326 transactions
Research
$27,080
13 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| VYNDAMAX CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $27,080 | 10 |
Top Doctors Receiving Payments for VYNDAMAX
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Cardiovascular Disease | Independence, OH | $21,439 | 5 |
| , M.D | Cardiovascular Disease | New York, NY | $18,928 | 5 |
| , MD | Internal Medicine | Stanford, CA | $17,424 | 6 |
| , MD, MPH | Internal Medicine | Chicago, IL | $12,165 | 10 |
| Unknown | — | Sacramento, CA | $9,360 | 7 |
| , M.D | Internal Medicine | Durham, NC | $8,400 | 2 |
| , DO FSVMB FACC | Cardiovascular Disease | Akron, OH | $8,312 | 6 |
| , M.D | Cardiovascular Disease | Weston, FL | $7,527 | 6 |
| , MD | Cardiovascular Disease | Norwich, CT | $7,204 | 3 |
| , M.D | Internal Medicine | New Brunswick, NJ | $6,650 | 3 |
| , MD | Advanced Heart Failure and Transplant Cardiology | La Jolla, CA | $6,250 | 4 |
| , M.D | Hematology & Oncology | Sacramento, CA | $6,040 | 1 |
| , MD | Cardiovascular Disease | Philadelphia, PA | $5,980 | 2 |
| , M.D | Cardiovascular Disease | Valhalla, NY | $5,850 | 1 |
| , M.D | Internal Medicine | Danville, PA | $5,788 | 2 |
| , M.D | Hematology & Oncology | Chicago, IL | $5,775 | 1 |
| , MD | Interventional Cardiology | Bismarck, ND | $5,670 | 1 |
| , DO | Pediatric Hematology-Oncology | Birmingham, AL | $5,625 | 1 |
| , M.D | Cardiovascular Disease | Teaneck, NJ | $5,478 | 3 |
| , MD | Cardiovascular Disease | Saint Louis, MO | $5,400 | 1 |
| , M.D | Internal Medicine | Falls Church, VA | $5,400 | 1 |
| , M.D | Internal Medicine | Santa Monica, CA | $5,175 | 2 |
| , D.O | Cardiovascular Disease | Weston, FL | $5,028 | 3 |
| , M.D | Cardiovascular Disease | Chicago, IL | $4,950 | 1 |
| , M.D., PH.D | Student in an Organized Health Care Education/Training Program | New York, NY | $4,950 | 1 |
Ad
Manufacturing Companies
- PFIZER INC. $486,380
- PFIZER CORPORATION HONG KONG LIMITED $223.73
- Pfizer Inc. $12.59
Product Information
- Type Drug
- Total Payments $486,617
- Total Doctors 4,345
- Transactions 6,339
About VYNDAMAX
VYNDAMAX is a drug associated with $486,617 in payments to 4,345 healthcare providers, recorded across 6,339 transactions in the CMS Open Payments database. The primary manufacturer is Pfizer Inc..
Payment data is available from 2019 to 2024. In 2024, $356,030 was paid across 3,160 transactions to 2,275 doctors.
The most common payment nature for VYNDAMAX is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($170,947, 35.1% of total).
VYNDAMAX is associated with 1 research study, including "VYNDAMAX CLINICAL PUBLICATION PROGRAM" ($27,080).